Precision Medicine

AstraZeneca and RenalytixAI to Collaborate to Develop Precision Medicine Strategies to Improve Outcomes for Patients with Chronic Disease

NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) — Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX),  today announced a collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases. The first stage in the collaboration will use KidneyIntelX, an artificial intelligence-enabled in vitro diagnostic platform, to examine …

Read More »

OneOncology and Foundation Medicine Unveil First-of-its-Kind Partnership to Advance Personalized Medicine at Community Oncology Practices

CAMBRIDGE, Mass. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Foundation Medicine, Inc. and OneOncology today announced a new joint initiative that is intended to better enable OneOncology partner practice physicians to unlock the potential of precision oncology through comprehensive genomic profiling (CGP) and research, informed by CGP and real world evidence. This unique partnership will …

Read More »

Janssen and GenCentric Enter Research Collaboration on Genomic Drug Response Biomarkers for Non-Muscle Invasive Bladder Cancer

DURHAM, N.C.–(BUSINESS WIRE)–GeneCentric Therapeutics today announced it has entered into a research collaboration with Janssen Research & Development, LLC (Janssen) around RNA-based drug response biomarkers for non-muscle invasive bladder cancer (NMIBC). The research will involve the application of GeneCentric’s advanced RNA-based molecular profiling platform to elucidate potential signatures of disease …

Read More »

Centogene and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and HEIDELBERG, Germany, July 27, 2020 (GLOBE NEWSWIRE) — Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, and Molecular Health, a leading company in …

Read More »

BD receives FDA Approval for HPV Test with Extended Genotyping Capabilities

FRANKLIN LAKES, N.J., July 22, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it received approval for a pre-market approval (PMA) supplement from the U.S. Food and Drug Administration (FDA) for an expanded version of its BD Onclarity™ HPV …

Read More »

Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have …

Read More »

Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases

SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (NASDAQ: ILMN) is bringing turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the TruSight™ Software Suite. TruSight Software delivers ready-made infrastructure to realize the full potential of whole-genome sequencing for rare genetic diseases. This new offering enables sample-to-report analysis …

Read More »

Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases

CAMBRIDGE, Mass., June 22, 2020 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, and Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, today announced a global research and option agreement to design …

Read More »

Invitae to Combine with ArcherDx to Create a Global Leader in Comprehensive Cancer Genetics and Precision Oncology

SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ — Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with …

Read More »

ArcherDX Enters Collaboration with Bristol Myers Squibb to Apply Personalized Cancer Monitoring to Clinical Research

BOULDER, Colo., June 18, 2020 /PRNewswire/ — ArcherDX, Inc. today announced it is entering into a collaboration with Bristol Myers Squibb (BMS) to utilize Personalized Cancer Monitoring (PCM™) assays to understand the potential benefits of minimal residual disease (MRD) detection in cancer patients treated with immunotherapy. PCM provides tumor-informed longitudinal …

Read More »